Treatment of type 2 diabetes mellitus

被引：35

作者：

Feinglos, MN

Bethel, MA

机构：

[1] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA

[2] Duke Univ, Med Ctr, Div Endocrinol & Metab, Durham, NC 27710 USA

来源：

MEDICAL CLINICS OF NORTH AMERICA | 1998年 / 82卷 / 04期

关键词：

D O I：

10.1016/S0025-7125(05)70023-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Although most patients with type 2 diabetes mellitus can be initially managed with diet and exercise alone, most eventually require at least oral agents if not insulin to maintain glycemic control. Appropriate therapeutic regimens may be difficult to design, given the diversity of drugs available for clinical use. Physicians must consider not only glycemic control, but also patient preference, concomitant medical conditions, and cost when designing therapeutic regimens.

引用

页码：757 / +

页数：36

共 122 条

[31] EFFICACY OF METFORMIN IN PATIENTS WITH NON-INSULIN-DEPENDENT DIABETES-MELLITUS [J].

DEFRONZO, RA ;

GOODMAN, AM ;

ABELOVE, W ;

REID, E ;

PITA, J ;

CALLAHAN, M ;

JOHNSON, D ;

PELAYO, E ;

PUGH, J ;

SHANK, M ;

GARZA, P ;

HAAG, B ;

KORFF, J ;

ANGELO, A ;

IZENSTEIN, B ;

VANDERLEEDEN, M ;

CATHCART, H ;

TIERNEY, M ;

BIGGS, D ;

KARAM, J ;

NOLTE, M ;

GAVIN, L ;

ELDER, MA ;

CORBOY, J ;

THWAITE, D ;

WONG, S ;

DAVIDSON, M ;

PETERS, A ;

DUNCAN, T ;

KERCHER, S ;

FISCHER, J ;

KIPNES, M ;

RADNICK, BJ ;

ROURA, M ;

ROQUE, J ;

MONTGOMERY, C ;

COLLUM, P ;

RUST, M ;

POHL, S ;

PFEIFER, M ;

ALLWEISS, P ;

LEICHTER, S ;

LEACH, P ;

GALLINA, D ;

MUSEY, V ;

BERKOWITZ, K ;

EASTMAN, R ;

TAYLOR, T ;

DELAPENA, MS ;

ZAWADSKI, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 333 (09) :541-549

[32] PATHOGENESIS OF NIDDM - A BALANCED OVERVIEW [J].

DEFRONZO, RA ;

BONADONNA, RC ;

FERRANNINI, E .

DIABETES CARE, 1992, 15 (03) :318-368

[33] Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study [J].

Dills, DG ;

Schneider, J ;

Aronoff, SL ;

Azorr, MA ;

Brunner, D ;

Cefalu, WT ;

Cohen, AJ ;

Cyrus, J ;

Freedman, Z ;

Haag, BL ;

Hamilton, BP ;

Littlejohn, TW ;

Lucas, CP ;

Matlock, JS ;

McGill, JB ;

Miller, SS ;

Nikolai, T ;

Ogilvie, JT ;

Podlecki, DA ;

Ricaurte, M ;

Roudebush, CP ;

Singh, SP ;

Smulovitz, J ;

Soler, NG ;

Stone, J ;

Stonesifer, LD ;

Tucker, WS ;

Wallum, BJ ;

White, J ;

Whittier, FC ;

Zieve, FJ .

HORMONE AND METABOLIC RESEARCH, 1996, 28 (09) :426-429

[34] Gene therapy for diabetes mellitus [J].

Docherty, K .

CLINICAL SCIENCE, 1997, 92 (04) :321-330

[35] CLINICAL PROFILE OF GLIMEPIRIDE [J].

DRAEGER, E .

DIABETES RESEARCH AND CLINICAL PRACTICE, 1995, 28 :S139-S146

[36] Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl(R)): A double-blind comparison with glibenclamide [J].

Draeger, KE ;

WernickePanten, K ;

Lomp, HJ ;

Schuler, E ;

Rosskamp, R .

HORMONE AND METABOLIC RESEARCH, 1996, 28 (09) :419-425

[37]

EDELMAN SV, 1995, DIABETES REV, V3, P308

[38]

Erhmann D, 1997, J CLIN ENDOCR METAB, V82, P2108

[39]

Eriksson J, 1997, DIABETOLOGIA, V40, P125

[40] Metformin's effects on glucose and lipid metabolism in patients with secondary failure to sulfonylureas [J].

Fanghanel, G ;

SanchezReyes, L ;

Trujillo, C ;

Sotres, D ;

EspinosaCampos, J .

DIABETES CARE, 1996, 19 (11) :1185-1189

← 1 2 3 4 5 6 7 8 9 10 →